Back to results
US 2014/0234316 A1Published application
Vaccibodies targeted to cross-presenting dendritic cells
AssigneeUniversity of Oslo
InventorsBjarne Bogen, Even Fossum, Gunnveig Grodeland
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant fusion proteins targeted to dendritic cells and uses thereof. In particular, the present invention relates to fusion proteins comprising an antibody component and a targeting components, and uses of such fusion proteins to trigger immune responses.
Claims12
A DNA vaccine comprising a pharmaceutically acceptable carrier and a nucleic acid encoding a fusion polypeptide comprising a targeting unit comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NOs 1, 2 or 3 and an antigenic unit.
10-12. (canceled)
(canceled)
Dependencies are inferred from the claim text.